PLUS1
0.64
0.13 (25.49%)
0.13 (25.49%)
Upgrade to Real-Time
Market Closed
Best deals to access real time data! |
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CV Sciences Inc (QB) | CVSI | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.13 | 25.49% | 0.64 | 0.49 | 0.75 | 0.5125 | 0.51 | 16:59:03 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.6211 | 0.665 | 0.0439 | 6.6% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,756 | 4,155,642 | $ 0.619339 | $ 2,573,751 | 791,935 | 0.25 - 5.99 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:59:58 | 1,000 | $ 0.64 | USD |
CV Sciences (QB) Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 64.24M | 100.38M | $ 10.00M | - | - | 82.68M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 1.20M | $ - | 0.00% | - | - |
CV Sciences (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/31/2020 | 17:17 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) |
| 3/30/2020 | 17:19 | Edgar (US Regulatory) | Annual Report (10-k) |
| 3/25/2020 | 16:50 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
| 3/25/2020 | 16:19 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 3/20/2020 | 17:21 | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting.. |
| 3/19/2020 | 19:00 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 3/16/2020 | 16:09 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CVSI Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.75995 | 0.77 | 0.49 | 0.6189395 | 599,244 | -0.11995 | -15.78% |
| 1 Month | 0.67 | 0.77 | 0.25 | 0.5113742 | 921,935 | -0.03 | -4.48% |
| 3 Months | 1.02 | 1.34 | 0.25 | 0.7812459 | 760,803 | -0.38 | -37.25% |
| 6 Months | 2.26 | 2.71 | 0.25 | 1.17 | 842,230 | -1.62 | -71.68% |
| 1 Year | 5.85 | 5.99 | 0.25 | 2.50 | 795,929 | -5.21 | -89.06% |
| 3 Years | 0.395 | 9.20 | 0.136 | 3.10 | 1,155,146 | 0.245 | 62.03% |
| 5 Years | 2.65 | 9.20 | 0.10 | 2.50 | 894,625 | -2.01 | -75.85% |
CV Sciences (QB) Description
| CV Sciences, Inc. is a life science company that operates through two segments, specialty pharmaceuticals and consumer products. The Company focuses on developing and commercializing proprietary prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient and is engaged in the development, manufacturing, marketing and sale of consumer products containing plant-based CBD, which is refined into its own proprietary branded products. CV Sciences initial drug candidate (CVSI-007) is a chewing gum that combines CBD and nicotine, which the Company believes has the potential to effectively treat smokeless tobacco use and addiction. The market for cessation of smokeless tobacco use and addiction is estimated at $2 billion, growing to over $4 billion in the next 5-6 years. |
